Hussman Strategic Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Hussman Strategic Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-84,000	Closed	-$2.08M	–	252
2026 Q1	$2.08M	Sell	84,000 -21,000	-20%	-$500K	0.45%	97
2025 Q4	$2.45M	Sell	105,000 -42,000	-29%	-$936K	0.59%	57
2025 Q3	$2.9M	Hold	147,000	–	–	0.63%	39
2025 Q2	$3.19M	Buy	147,000 +63,000	+75%	+$1.49M	0.73%	40
2025 Q1	$2.04M	Sell	84,000 -21,000	-20%	-$473K	0.49%	80
2024 Q4	$2.19M	Hold	105,000	–	–	0.65%	51
2024 Q3	$2.09M	Hold	105,000	–	–	0.51%	88
2024 Q2	$1.63M	Hold	105,000	–	–	0.45%	99
2024 Q1	$1.67M	Sell	105,000 -52,500	-33%	-$791K	0.39%	101
2023 Q4	$2.65M	Hold	157,500	–	–	0.6%	59
2023 Q3	$1.84M	Buy	157,500 +64,500	+69%	+$863K	0.35%	119
2023 Q2	$1.25M	Hold	93,000	–	–	0.23%	188
2023 Q1	$1.54M	Buy	93,000 +31,000	+50%	+$511K	0.24%	172
2022 Q4	$1.15M	Hold	62,000	–	–	0.19%	187
2022 Q3	$795K	Sell	62,000 -68,000	-52%	-$806K	0.14%	229
2022 Q2	$911K	Buy	130,000 +62,000	+91%	+$455K	0.16%	210
2022 Q1	$564K	Hold	68,000	–	–	0.11%	248
2021 Q4	$460K	Sell	68,000 -56,000	-45%	-$368K	0.1%	256
2021 Q3	$657K	Hold	124,000	–	–	0.14%	210
2021 Q2	$713K	Buy	+124,000	New	+$640K	0.15%	229

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hussman Strategic Advisors's CPRX Position: Q2 2026 in Review

Hussman Strategic Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 84,000 shares — an estimated $2.08M sold.

Hussman Strategic Advisors first reported a position in CPRX in Q2 2021 and held it in 20 quarters. The position peaked at $3.19M in Q2 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Hussman Strategic Advisors reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Hussman Strategic Advisors sold 84,000 Catalyst Pharmaceutical shares in Q2 2026, an estimated $2.08M.
Hussman Strategic Advisors first reported a position in Catalyst Pharmaceutical in Q2 2021 and held it in 20 quarters.
Hussman Strategic Advisors's Catalyst Pharmaceutical position peaked at $3.19M in Q2 2025.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.